Employees: 146
Size Prime Medicine (PRME) is a United States Health Care company (Biotechnology) with a market value of $695M, the 2463rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.82 on 18 Nov 2026.
Performance Over six months the shares gained 35.0%, against -23.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue grew 18.1% over the last twelve months (peer median +13.3%); the operating margin is -2,584.2% (peer median -76.8%).
Valuation It trades at 105.4× enterprise value to sales against a peer median of 6.9× (3rd most expensive of 16).
Short interest Short interest is 16.1% of the free float (30 Oct 2026).
Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $7.06M | $4.63M | $2.98M | $0 | $0 |
| Revenue growth | — | +55% | — | — | — |
| Gross profit | -$215,000 | -$2.69M | -$3.15M | -$4.65M | -$12.0M |
| EBITDA | -$175M | -$201M | -$196M | -$187M | -$105M |
| Net income | -$176M | -$201M | -$196M | -$198M | -$122M |
| Free cash flow | -$159M | -$167M | -$130M | -$174M | -$148M |
| Capital expenditure | $848,000 | $4.53M | $7.29M | $8.72M | $16.1M |
| Total debt | $110M | $116M | $40.8M | $13.6M | $28.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PRME | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.5% | -7.3% | 7th highest of 21 |
| 6-month return | +35.0% | -23.5% | 4th highest of 19 |
| Distance from 52-week high | -35.4% | -47.7% | 5th highest of 21 |
| Revenue growth (TTM) | +18.1% | +13.3% | 8th highest of 15 |
| Operating margin | -2,584.2% | -76.8% | 3rd lowest of 17 |
| EV / Sales | 105.4× | 6.9× | 3rd most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | 12,169.8× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |